Research > Team II:Structure-Based Drug Design Discovery



Name Na Yang
Research Area Structural Biology, Epigenetics
Tel 022-23506290
E-mail yangnNKU@163.com
Brief
Introduction
Dr. Na Yang received her Bachelor’s degree in Biophysics from Peking University in 2000 and her PhD degree from Institute of Biophysics, Chinese Academy of Sciences (CAS) in 2005. She performed postdoctoral training at Peking University from 2006 to 2008, and joined the faculty of Institute of Biophysics at the end of 2008, first as an Associate Investigator, and subsequently as an Investigator in 2013 and Professor of the University of CAS in 2015. In early 2017, Dr. Yang became Professor of Pharmacology at Nankai University and Principle Investigator of State Key Laboratory of Medicinal Chemical Biology.
Dr. Yang has been carrying out studies of structural basis of epigenetics, including histone modifications and nucleosome assembly, as well as RNA-protein interactions in mRNA localization. The main research interest of Dr. Yang’s group is on drug target validation of epigenetic factors closely related to human diseases, such as malignant tumor. The lab principally uses structure-based approaches, by solving the three-dimensional structures of these epigenetic factors, to reveal the relationship between their structures and functions. Followed by virtual screening and rational drug design based on these structures. Finally candidate compounds will be evaluated and optimized by iterative Structure-Activity Relationship (SAR) analyses. She has published 32 research articles in prestigious scientific journals such as Science, NSMB, PNAS, Genes & Dev., JBC, etc.
Dr. Yang is the winner of National Excellent Young Scientist Award and Hundred Young Academic Leader of Nankai University.She is currently the secretary general of Molecular Biophysics Section of the Chinese Biophysical Society, committee member of the Chinese Crystallographic Society, and consultant of Biological Macromolecules Commission of the International Union of Crystallography (IUCr).
Resent Publications (in 5 years)
1. Fu, W. Q., Liu, N., Qiao, Q., Wang, M., Min, J. R., Zhu, B.*, Xu, R. M.* and Yang, N.* (2016) Structural Basis for Substrate Preference of SMYD3, A SET Domain-containing Protein Lysine Methyltransferase. Journal of Biological Chemistry, Vol. 291, 9173-9180.
2.Fang, D., Gan, H., Lee, J. H., Han, J., Wang, Z., Riester, S. M., Jin, L., Chen, J., Zhou, H., Wang, J., Zhang, H., Yang, N., Bradley, E. W., Ho, T. H., Rubin, B. P., Bridge, J. A., Thibodeau, S. N., Ordog, T., Chen, Y., van Wijnen, A. J., Oliveira, A. M., Xu, R. M., Westendorf, J. J. and Zhang, Z.* (2016) The histone H3.3K36M mutation reprograms the epigenome of chondroblastomas. Science,Vol. 29, 1316-1325.
3. Yang, N.*, Yu, Z. Y., Hu, M. L.,Wang, M., Lehmann, R.* and Xu, R. M.* (2015) Structure of Drosophila Oskar reveals a novel RNA binding protein. Proc. Natl. Acad. Sci .USA, Vol. 112, 11541-11546.
4. Cao, D.F., Wang, M., Qiu X.Y., Liu D.X., Jiang H.L., Yang, N.* and Xu R.M.* (2015) Structural basis for allosteric, substratedependentstimulation of SIRT1 activityby resveratrol. Genes & Development, Vol. 29, 1316-1325.
5. Wang, H., Wang, M., Yang, N.* and Xu, R. M.*(2015) Structure of the quaternary complex of histone H3-H4 heterodimer with chaperone ASF1 and the replicative helicase subunit MCM2. Protein & Cell, Vol. 6, 693-697.
6. Yang, D. X., Fang, Q. L., Wang, M., Ren, R., Wang, H., He, M., Sun, Y. W., Yang, N.* and Xu, R. M.* (2013) Nα-acetylated Sir3 stabilizes the conformation of a nucleosome-binding loop in the BAH domain. Nature Structural & Molecular Biology, Vol. 20, 1116-1118.
7. Yang, N.* and Xu, R. M.* (2013) Structure and function of the BAH domain in chromatin biology. Critical Reviews in Biochemistry &Molecular Biology, Vol. 48, 211-221.
8. Yang, N.*, Wang, W., Wang, Y., Wang, M., Zhao, Q., Rao, Z., Zhu, B.* and Xu, R. M.* (2012) Distinct mode of methyl-H3K4 recognition by tandem tudor-like domains of Spindlin1. Proc. Natl. Acad. Sci .USA, Vol. 109, 17954-17959.